Advertisement

European Journal of Dermatology

, Volume 27, Issue 6, pp 656–658 | Cite as

Nivolumab-induced vitiligo successfully treated with narrowband UVB phototherapy

  • Takuya Miyagawa
  • Takafumi KadonoEmail author
  • Yuri Masui
  • Daisuke Yamada
  • Ryosuke Saigusa
  • Hiroko Numajiri
  • Jun Omatsu
  • Yoshihide Asano
  • Shinichi Sato
Correspondence
  • 23 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22: 886–94.CrossRefGoogle Scholar
  2. 2.
    Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12–25.CrossRefGoogle Scholar
  3. 3.
    Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008; 159: 931–5.CrossRefGoogle Scholar
  4. 4.
    Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114–35.CrossRefGoogle Scholar
  5. 5.
    Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 2004; 140: 677–83.CrossRefGoogle Scholar
  6. 6.
    Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (Check-Mate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16: 257–65.CrossRefGoogle Scholar
  7. 7.
    Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J Clin Oncol 2015; 33: 1430–7.CrossRefGoogle Scholar
  8. 8.
    Klein O, Ebert LM, Nicholaou T, et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009; 15: 2507–13.CrossRefGoogle Scholar
  9. 9.
    Larsabal M, Marti A, Jacquemin C, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol 2017; 76: 863–70.CrossRefGoogle Scholar
  10. 10.
    Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat 2009; 20: 14–8.CrossRefGoogle Scholar

Copyright information

© JLE/Springer 2018

Authors and Affiliations

  • Takuya Miyagawa
    • 1
  • Takafumi Kadono
    • 2
    Email author
  • Yuri Masui
    • 1
  • Daisuke Yamada
    • 1
  • Ryosuke Saigusa
    • 1
  • Hiroko Numajiri
    • 1
  • Jun Omatsu
    • 1
  • Yoshihide Asano
    • 1
  • Shinichi Sato
    • 1
  1. 1.Department of DermatologyUniversity of Tokyo Graduate School of MedicineTokyoJapan
  2. 2.Department of DermatologySt. Marianna University School of MedicineKanagawaJapan

Personalised recommendations